Transdermal therapeutic systems containing 4-n-butyl-resorcinol

Abstract

A method for the treatment of a local pigmentation disorder comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient.

What is claimed is: 
     
         1 . A method for the treatment of a local pigmentation disorder, wherein the method comprises applying to skin affected by the disorder a transdermal therapeutic system which comprises 4-n-butylresorcinol as an active ingredient. 
     
     
         2 . The method of  claim 1 , wherein the local pigmentation disorder comprises local hyperpigmentation. 
     
     
         3 . The method of  claim 1 , wherein the local pigmentation disorder comprises age spots. 
     
     
         4 . The method of  claim 1 , wherein the local pigmentation disorder comprises freckles. 
     
     
         5 . The method of  claim 1 , wherein the local pigmentation disorder comprises post-inflammatory hyperpigmentation. 
     
     
         6 . The method of  claim 1 , wherein the local pigmentation disorder comprises melasma. 
     
     
         7 . The method of  claim 1 , wherein the transdermal therapeutic system is employed in the form of a self-adhesive flat bandage. 
     
     
         8 . The method of  claim 1 , wherein the transdermal therapeutic system is employed in the form of at least one of a cosmetic plaster and a medicinal plaster. 
     
     
         9 . The method of  claim 1 , wherein the transdermal therapeutic system is employed in the form of a matrix system. 
     
     
         10 . The method of  claim 9 , wherein the matrix is selected from nonpolar matrices based on synthetic and natural rubber, polar wet adhesive films based on polyacrylic acid/polyvinyl alcohol, nonpolar matrices based on polyacrylic acid copolymers, polar anhydrous gel matrices based on polyacrylic acid/polyvinylpyrrolidone, nonpolar polyisobutylene matrices, and polar water gel matrices based on agar agar/polyacrylic acid. 
     
     
         11 . The method of  claim 9 , wherein the matrix is selected from polyisobutylene matrices. 
     
     
         12 . The method of  claim 9 , wherein the matrix is selected from water gel matrices based on agar agar/polyacrylic acid. 
     
     
         13 . The method of  claim 1 , wherein the transdermal therapeutic system comprises from 0.001% to 10% by weight of 4-n-butylresorcinol, based on a total weight of the system. 
     
     
         14 . The method of  claim 1 , wherein the transdermal therapeutic system comprises from 0.01% to 1% by weight of 4-n-butylresorcinol. 
     
     
         15 . The method of  claim 11 , wherein the matrix has a layer thickness of from 0.15 mm to 1.00 mm. 
     
     
         16 . The method of  claim 12 , wherein the matrix has a layer thickness of from 0.15 mm to 1.00 mm. 
     
     
         17 . The method of  claim 11 , wherein the matrix has a layer thickness of from 0.20 mm to 0.50 mm. 
     
     
         18 . The method of  claim 12 , wherein the matrix has a layer thickness of from 0.20 mm to 0.50 mm. 
     
     
         19 . The method of  claim 1 , wherein the transdermal therapeutic system comprises from 0.001% to 10% by weight of one or more penetration accelerators. 
     
     
         20 . The method of  claim 19 , wherein the one or more penetration accelerators comprise at least one of isopropyl palmitate and isopropyl myristate.